Top Markets
Coin of the day
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Rangering i aksjer #16730
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Aksjekurs
$3.78
Sist synkronisert: 2026-03-17
Markedsverdi
$276.54M
Endring (1 dag)
0.00%
Endring (1 år)
45.53%
Land
CA
Handel NervGen Pharma Corp. (NGEN)

Kategori

Inntekter for NervGen Pharma Corp. (NGEN)
Inntekter i 2026 TTM: 0
Ifølge NervGen Pharma Corp. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for NervGen Pharma Corp. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH